Clinical Trial
-
Biologics
BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
First Patient Enrollment Milestone Completed MELVILLE, NY., June 30, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ:…
Read More » -
Spine
3Spine, Inc. Completes First US Surgeries
CHATTANOOGA, Tenn., June 29, 2022 /PRNewswire/ — 3Spine, Inc., a medical device company developing total joint replacement for the lumbar spine, today…
Read More » -
Spine
3Spine, Inc. Announces IDE Approval
CHATTANOOGA, Tenn., June 22, 2022 /PRNewswire/ — 3Spine, Inc., a medical device company developing total joint replacement for the lumbar spine, today…
Read More » -
Biologics
BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
MELVILLE, NY., June 22, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused…
Read More » -
Biologics
Ortho Regenerative Technologies Initiates Patients Recruitment For Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial
Contracting procedures completed for 6 of the 10 clinical trial sites5 sites fully activated, with ongoing patients’ screening and recruitment…
Read More » -
Spine
Clinical Trial to Test Replacement Devices for Two-Level Symptomatic Cervical Disc Disease
NEW YORK, June 1, 2022 /PRNewswire/ — A multicenter, prospective, randomized controlled trial is designed to assess the effectiveness of three different disc replacement…
Read More » -
Biologics
First Subjects Randomized and Dosed in the U.S. under Phase III Pivotal Trial for the Treatment of Pain Associated with Knee OA
Ongoing trial to assess the potential of Zilosul™ to address unmet medical need in OA which affects more than 72 million…
Read More » -
Spine
Spineart-100 U.S. Patients Treated In The Single Level IDE Clinical Trial Of BAGUERA®C Cervical Disc Prosthesis
LAGUNA HILLS, Calif., April 21, 2022 /PRNewswire/ — Spineart USA Inc. announced today that surgery has been performed on 100 patients in the single-level U.S.…
Read More » -
Spine
BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
MELVILLE, N.Y.,, April 18, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage…
Read More » -
Biologics
Ortho Regenerative Technologies Enters Into A Material Transfer Agreement With A Global Strategic Medical Company For Its Ortho-R Rotator Cuff Tear Repair Phase I/II U.S. Clinical Trial
MONTREAL, Feb. 7, 2022 /PRNewswire/ – Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTC: ORTIF) (“Ortho” or the “Company“), a clinical-stage orthobiologics company focused on…
Read More » -
Spine
Mainstay Medical Announces Publication of Two-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™
Data shows compelling efficacy and safety, as well as improvement on all key measures of pain and disability as compared…
Read More » -
Spine
BioRestorative Therapies Announces CRO Agreement with PRC Clinical for its BRTX-100 Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
MELVILLE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ:BRTX), a life sciences company…
Read More » -
Biologics
Ortho Regenerative Technologies Announces U.S. IND Clinical Hold Lifted By The FDA & Clearance To Proceed With U.S. Clinical Trial
MONTREAL, Dec. 13, 2021 /PRNewswire/ – Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTCQB: ORTIF) (“Ortho” or the “Company”), a clinical-stage orthobiologics company focused on the…
Read More » -
Hospitals
HSS and Rothman Institute/Jefferson University Hospital to Participate in Clinical Trial for Elute’s Antibiotic Loaded Bone Void Filler
SALT LAKE CITY, Nov. 30, 2021 /PRNewswire/ — Following Elute, Inc.’s Investigational Device Exemption (IDE) authorization from the US Food and Drug Administration (FDA)…
Read More » -
Biologics
Ortho Regenerative Technologies Receives Clinical Hold Letter From the U.S. FDA
Additional CMC related data and characterization requested by the FDACompany confident of providing requested information over the coming weeksPhase I/II…
Read More »